UniQure doubles on alignment with FDA on development plan for gene therapy

uniQure

10/12/2024 19:16

(Updates)
    ** U.S.-listed shares of Netherlands-based UniQure NV
 UQ1.F   QURE.O  jump as much as 138.2% to a more than one-year
high of $17.39
        ** Stock set for its best day ever, if gains hold
  
    ** Drugmaker says it has reached an agreement with the U.S.
FDA on key elements for an accelerated approval path for its 
Huntingdon's disease therapy, AMT-130
    ** The FDA agreed data from ongoing early-to-mid stage
studies may serve as primary basis for submission for potential
approval, avoiding the need for an additional pre-submission
study, QURE says
    ** Huntington's disease is a rare, inherited
neurodegenerative disorder
    ** Including session's moves, stock has more than doubled
YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))